The addition of mesna to hyperhydration does not decrease the incidence of hemorrhagic cystitis in patients receiving
C Murphy1, E Harden, D Stevens
1JAMES RIVER CLIN,NEWPORT NEWS,VA 23606. W VIRGINIA UNIV,HLTH SCI CTR,DEPT MED,MARY BABB CANC CTR,BONE MARROW TRANSPLANTAT PROGR,MORGANTOWN,WV 26506. UNIV LOUISVILLE,JAMES GRAHAM BROWN CANC CTR,LOUISVILLE,KY 40292.
Abstract:
To assess the efficacy of hyperhydration Versus hyperhydration plus mesna in preventing cyclophosphamide induced hemorrhagic cystitis a retrospective analysis was conducted of 110 patients who received hyperhydration alone (baseline intravenous intake of at least 3.6 1/m(2)/day) and 107 patients who received hyperhydration plus mesna (120% of daily cyclophosphamide dose) while receiving cyclophosphamide (total dose 150-200 mg/kg) as part of a dose intensive regimen. Macroscopic hematuria was noted in 17 (16%) and 9 (8%) patients who received hyperhydration with or without mesna, respectively (p=0.08). This analysis failed to demonstrate a benefit in adding mesna to hyperhydration alone in preventing cyclophosphamide induced hemorrhagic cystitis.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Hemodialysis II: Procedure and Complications
Hemodialysis III: Nursing Management
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Antihypertensive Drugs: Thiazide-Class Diuretics
Acute Kidney Injury IV: Diagnostic Studies and Prevention
